Renal cell cancer

Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIM^SM registry
M. Fishman, J. P. Dutcher, J. I. Clark, A. Alva, G. P. Miletello, B. Curti, Neeraj Agarwal, R. Hauke, K. M. Mahoney, H. Moon, J. Treisman, S. S. Tykodi, G. Daniels, M. A. Morse, M. K. K. Wong, H. Kaufman, N. Gregory, D. F. McDermott

Journal for ImmunoTherapy of Cancer Dec 2019, 7 (1) 84; DOI: 10.1186/s40425-019-0567-3
Perspectives in immunotherapy: meeting report from the “Immunotherapy Bridge”, Napoli, December 5^th 2015
Paolo A. Ascierto, Maria Libera Ascierto, Silvia Formenti, Sacha Gnjatic, Hans Hammers, Vera Hirsh, Rolf Kiessling, Ignacio Melero, Rita Nanda, Graham Pawelec, Sandro Pignata, Pedro Romero, Daniel E. Speiser, Bernard A. Fox, Francesco M. Marincola

Journal for ImmunoTherapy of Cancer Dec 2016, 4 (1) 62; DOI: 10.1186/s40425-016-0168-3
Tumor control with PD-1 inhibition in a patient with concurrent metastatic melanoma and renal cell carcinoma
Melina E. Marmarelis, Meredith R. Davis, Nilay S. Sethi, Katherine M. Krajewksi, Rana R. McKay, Toni K. Choueiri, Patrick A. Ott

Journal for ImmunoTherapy of Cancer Dec 2016, 4 (1) 26; DOI: 10.1186/s40425-016-0129-x

Main menu